Last reviewed · How we verify
Red blood cells concentrate
At a glance
| Generic name | Red blood cells concentrate |
|---|---|
| Sponsor | Banc de Sang i Teixits |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Platelet Rich Plasma for Musculoskeletal Conditions (NA)
- Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (PHASE3)
- Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment. (NA)
- A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease (PHASE3)
- A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises (PHASE3)
- Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
- Erythrocyte Transfusion Based on the Measurement of Central Venous Oxygen Saturation in Postoperative Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Red blood cells concentrate CI brief — competitive landscape report
- Red blood cells concentrate updates RSS · CI watch RSS
- Banc de Sang i Teixits portfolio CI